COMPANY

Unravel Biosciences

Keywords: neurology amyotrophic lateral sclerosis long COVID metabolic Pitt Hopkins Syndrome Rett Syndrome Vorinostat (SAHA)

Location: Medford, MA · source · Oct 12, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $4.1M in debt securities (Form D filed Aug 24, 2026). SEC Form D 0001876967-26-000002 (Aug 24, 2026)
Evidence (1 event)
- Aug 24, 2026 · SEC Form D 0001876967-26-000002
  Name of Issuer: Unravel Biosciences, Inc.; CIK: 1876967; Address: Medford, MA; Submission type: D; Filing date: 2026-08-24; Industry Group: Biotechnology; Date of First Sale: 2026-08-07; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 4500000; Total Amount Sold: 4100000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Mar 15, 2026 Trial start Phase 1: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome source ↗
Mar 15, 2026 Trial start Phase 1: Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome source ↗

Dec 31, 2026 (ESTIMATED) · Phase 1 · An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome · NCT07150026
Dec 31, 2026 (ESTIMATED) · Phase 1 · Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome · NCT07150013

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07150026	An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome	Phase 1	Recruiting	Mar 15, 2026	Dec 31, 2026 (estimated)
NCT07150013	Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome	Phase 1	Recruiting	Mar 15, 2026	Dec 31, 2026 (estimated)